Hamid Dolatshad

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

Application of CRISPR/Cas9 genome editing to the study and treatment of disease.

A versatile transgenic allele for mouse overexpression studies.

Application of genome editing technologies to the study and treatment of hematological disease.

ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.

Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.